ArticleGenome medicine2026
Multi-modal data integration reveals functionally credible predictive biomarkers in ovarian cancer.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrecision oncology aims to tailor treatment according to tumor-specific molecular alterations, but the success of aberration-guided therapies has been limited in clinical trials. Here, we develop an integrated whole-genome and transcriptome workflow to systematically distinguish functionally credible, predictive driver aberrations from non-functional alterations across all classes of genomic events.
methodsWe applied the integrated omics workflow to 335 patients with ovarian high-grade serous carcinoma (HGSC) enrolled in the observational DECIDER study. Tumor samples were collected from multiple cancer sites as part of the standard cancer care. DNA and RNA were extracted together from snap-frozen tumor samples and sent to whole-genome and transcriptome sequencing. Sequencing data were processed with the Anduril 2 pipeline for detection and validation of short somatic changes and with the HMW toolkit and the nf-core/rnafusion pipeline for assessment of structural changes. Aberration-specific drug sensitivity was tested in patient-derived organoids with a drug screen combining targeted agents and chemotherapy.
resultsUsing an agnostic integrated omics analysis, we identified clinically relevant ESCAT Tier II-III alterations in more than 40% of the patients, even though 58% of all nominally pathogenic variants proved to be false positives. Credible aberrations were predominantly clonal, detected across anatomical sites, and preserved from diagnosis to relapse, indicating early establishment during tumor evolution. The most recurrent actionable event was NF1 deficiency, which was associated with a robust transcriptional footprint and marked sensitivity to KRAS- and MEK-inhibition in patient-derived organoids. Notably, integrated DNA-RNA analysis enabled discrimination of treatment-guiding aberrations from false-positive findings that would otherwise misinform treatment selection and confound clinical trial outcomes.
conclusionsOur findings provide a strategy for more reliable biomarker detection in precision oncology, inform biomarker-guided clinical trial design, and reveal unexploited therapeutic vulnerabilities in HGSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.